Leukeran and Chronic obstructive pulmonary disease - a phase IV clinical study of FDA data

Summary:

Chronic obstructive pulmonary disease is found among people who take Leukeran, especially for people who are female, 60+ old, have been taking the drug for 1 - 2 years.

The phase IV clinical study analyzes which people take Leukeran and have Chronic obstructive pulmonary disease. It is created by eHealthMe based on reports of 1,065 people who have side effects when taking Leukeran from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

With medical big data and AI algorithms, eHealthMe enables everyone to run phase IV clinical trial to detect adverse drug outcomes and monitor effectiveness. Our original studies have been referenced on 600+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Most recently, phase IV clinial trails for COVID 19 vaccines have been added, check here.



On Jun, 30, 2022

1,065 people reported to have side effects when taking Leukeran.
Among them, 10 people (0.94%) have Chronic obstructive pulmonary disease.


What is Leukeran?

Leukeran has active ingredients of chlorambucil. eHealthMe is studying from 1,079 Leukeran users for its effectiveness, alternative drugs and more.

What is Chronic obstructive pulmonary disease?

Chronic obstructive pulmonary disease (a progressive disease that makes it hard to breathe) is found to be associated with 2,637 drugs and 1,964 conditions by eHealthMe.

Number of Leukeran and Chronic obstructive pulmonary disease reports submitted per year:

Could Leukeran cause Chronic obstructive pulmonary disease?

Time on Leukeran when people have Chronic obstructive pulmonary disease *:

  • < 1 month: 0.0 %
  • 1 - 6 months: 0.0 %
  • 6 - 12 months: 0.0 %
  • 1 - 2 years: 100 %
  • 2 - 5 years: 0.0 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

Gender of people who have Chronic obstructive pulmonary disease when taking Leukeran *:

  • female: 90 %
  • male: 10 %

Age of people who have Chronic obstructive pulmonary disease when taking Leukeran *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 0.0 %
  • 50-59: 0.0 %
  • 60+: 100 %

Common drugs people take besides Leukeran *:

  1. Zometa: 6 people, 60.00%
  2. Aredia: 6 people, 60.00%
  3. Ativan: 5 people, 50.00%
  4. Zocor: 5 people, 50.00%
  5. Kenalog: 4 people, 40.00%
  6. Protonix: 4 people, 40.00%
  7. Glipizide: 4 people, 40.00%
  8. Prilosec: 4 people, 40.00%
  9. Premarin: 4 people, 40.00%
  10. Glutamine: 4 people, 40.00%

Common side effects people have besides Chronic obstructive pulmonary disease *:

  1. High Blood Pressure: 8 people, 80.00%
  2. Fever: 7 people, 70.00%
  3. Anaemia (lack of blood): 7 people, 70.00%
  4. Mitral Valve Incompetence (inefficient heart valve): 6 people, 60.00%
  5. Rashes (redness): 6 people, 60.00%
  6. Pneumonia: 6 people, 60.00%
  7. Depression: 6 people, 60.00%
  8. Aortic Arteriosclerosis (hardening of the aortic arteries): 6 people, 60.00%
  9. Chest Pain: 6 people, 60.00%
  10. Arrhythmias (irregular heartbeat): 6 people, 60.00%

Common conditions people have *:

  1. Multiple Myeloma (cancer of the plasma cells): 6 people, 60.00%
  2. Immunodeficiency Disorders: 4 people, 40.00%
  3. Aseptic Necrosis (the death of bone tissue due to a lack of blood supply): 4 people, 40.00%
  4. Chronic Lymphocytic Leukaemia (cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell)): 3 people, 30.00%
  5. Pain: 2 people, 20.00%
  6. Small Intestinal Bacterial Overgrowth: 1 person, 10.00%
  7. Metastatic Renal Cell Carcinoma (spreadable kidney cell tumour): 1 person, 10.00%

* Approximation only. Some reports may have incomplete information.

Do you take Leukeran and have Chronic obstructive pulmonary disease?

Check whether Chronic obstructive pulmonary disease is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related studies

Alternative drugs to, pros and cons of Leukeran:

Chronic obstructive pulmonary disease treatments and more:

COVID vaccines that are related to Chronic obstructive pulmonary disease:

How severe was Chronic obstructive pulmonary disease and when was it recovered:

Expand to all the drugs that have ingredients of chlorambucil:

Common drugs associated with Chronic obstructive pulmonary disease:

All the drugs that are associated with Chronic obstructive pulmonary disease:

Common conditions associated with Chronic obstructive pulmonary disease:

All the conditions that are associated with Chronic obstructive pulmonary disease:

How the study uses the data?

The study uses data from the FDA. It is based on chlorambucil (the active ingredients of Leukeran) and Leukeran (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: